Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2022 Publisher: AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge, CB2 0AA, UK
Bricanyl Tablets 5mg.
| Pharmaceutical Form |
|---|
|
Tablet. Off white, circular, biconvex tablet, engraved A/BT and scored on one side, symbol ‘5’ on the reverse. |
Each tablet contains 5mg terbutaline sulfate.
Excipient(s) with known effect: Each Bricanyl Tablet contains 104 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Terbutaline |
Terbutaline is a selective beta2-adrenoceptor agonist, thus producing relaxation of bronchial smooth muscle, inhibition of the release of endogenous spasmogens, inhibitions of oedema caused by endogenous mediators, increased mucociliary clearance and relaxation of the uterine muscle. |
| List of Excipients |
|---|
|
Lactose monohydrate |
Glass bottles and Securitainers of 100 and 500 tablets.
Not all pack sizes may be marketed.
AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge, CB2 0AA, UK
PL 17901/0116
Date of first authorisation: 28th May 2002
Date of latest renewal: 15th May 2007
| Drug | Countries | |
|---|---|---|
| BRICANYL | Austria, Australia, Brazil, Canada, Estonia, Finland, France, Hong Kong, Ireland, Japan, Malta, Netherlands, New Zealand, Tunisia, Turkey, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
